Obesity drugs under siege
Interneuron Pharmaceuticals Inc.'s Redux dexfenfluramine is taking a growing beating in the scientific literature, as anecdotal evidence of significant side effects is starting to trickle in. Partner Wyeth-Ayerst last week scrambled to keep up, announcing that it is working with Mayo Clinic Researchers to evaluate any links between valvular heart disease and weight loss drugs.
In July, Mayo researchers announced a possible association between rare heart valve disorders and fenfluramine-phentermine (fen-phen) obesity therapy (see BioCentury July 14).
At that time, the FDA issued a letter alerting health care professionals to the findings. The agency has reissued a warning noting that more cases